| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | 'Contrast Enhanced Magnetic Resonance Angiography' | |
Result : Searchterm 'Contrast Enhanced Magnetic Resonance Angiography' found in 1 term [] and 13 definitions [], (+ 5 Boolean[] results
| previous 11 - 15 (of 19) nextResult Pages : [1] [2 3] [4] | | | | Searchterm 'Contrast Enhanced Magnetic Resonance Angiography' was also found in the following service: | | | | |
| | | | | | | |
| |
|
| | | | | | | | | | | • View the DATABASE results for 'Time of Flight Angiography' (11).
| | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
( USPIO) The class of the ultrasmall superparamagnetic iron oxide includes several chemically and pharmacologically very distinct materials, which may or may not be interchangeable for a specific use. Some ultrasmall SPIO particles (median diameter less than 50nm) are used as MRI contrast agents ( Sinerem®, Combidex®), e.g. to differentiate metastatic from inflammatory lymph nodes. USPIO shows also potential for providing important information about angiogenesis in cancer tumors and could possibly complement MRI helping physicians to identify dangerous arteriosclerosis plaques.
Because of the disadvantageous large T2*//T1 ratio, USPIO compounds are less suitable for arterial bolus contrast enhanced magnetic resonance angiography than gadolinium complexes. The tiny ultrasmall superparamagnetic iron oxides do not accumulate in the RES system as fast as larger particles, which results in a long plasma half-life.
USPIO particles, with a small median diameter (less than 10 nm), will accumulate in lymph nodes after an intravenous injection by e.g. direct transcapillary passage through endothelial venules. Once within the nodal parenchyma, phagocytic cells of the mononuclear phagocyte system take up the particles.
As a second way, USPIOs are subsequently taken up from then interstitium by lymphatic vessels and transported to regional lymph nodes. A lymph node with normal phagocytic function takes up a considerable amount and shows a reduction of the signal intensity caused by T2 shortening effects and magnetic susceptibility. Caused by the small uptake of the USPIOs in metastatic lymph nodes, they appear with less signal reduction, and permit the differentiation of healthy lymph nodes from normal-sized, metastatic nodes.
See also Superparamagnetic Contrast Agents, Superparamagnetic Iron Oxide, Very Small Superparamagnetic Iron Oxide Particles, Blood Pool Agents, Intracellular Contrast Agents. | | | | • View the DATABASE results for 'Ultrasmall Superparamagnetic Iron Oxide' (16).
| | | • View the NEWS results for 'Ultrasmall Superparamagnetic Iron Oxide' (2).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | Searchterm 'Contrast Enhanced Magnetic Resonance Angiography' was also found in the following service: | | | | |
| | |
| |
|
Vasovist™ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovist™ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovist™ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVAR™), to Lantheus Medical Imaging, Inc..
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m 2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.
See also MRI Safety.
Drug Information and Specification NAME OF COMPOUND Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325 T1, predominantly positive enhancement 20-45 mmol-1sec-1, Bo=0,47T PHARMACOKINETIC Intravascular, short elimination half life CONCENTRATION 244 mg/mL, 0.25mmol/mL DOSAGE 0.12 mL/kg, 0.03 mmol/kg DEVELOPMENT STAGE approved DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information TERRITORY TRADE NAME DEVELOPMENT STAGE DISTRIBUTOR North America, Australia for sale | | | | • View the DATABASE results for 'Vasovist™' (7).
| | | | Further Reading: | Basics:
|
|
| |
| | | | | |
| |
|
From GE Healthcare;
The Signa HDx MRI system is GE's leading edge whole body magnetic resonance scanner designed to support high resolution, high signal to noise ratio, and short scan times.
Signa HDx 3.0T offers new technologies like ultra-fast image reconstruction through the new XVRE recon engine, advancements in parallel imaging algorithms and the broadest range of premium applications. The HD applications, PROPELLER (high-quality brain imaging extremely resistant to motion artifacts), TRICKS ( contrast- enhanced angiographic vascular lower leg imaging), VIBRANT (for breast MRI), LAVA (high resolution liver imaging with shorter breath holds and better organ coverage) and MR Echo (high-definition cardiac images in real time) offer unique capabilities.
Device Information and Specification CLINICAL APPLICATION Whole body
CONFIGURATION Compact short bore SE, IR, 2D/3D GRE, RF-spoiled GRE, 2DFGRE, 2DFSPGR, 3DFGRE, 3DFSPGR, 3DTOFGRE, 3DFSPGR, 2DFSE, 2DFSE-XL, 2DFSE-IR, T1-FLAIR, SSFSE, EPI, DW-EPI, BRAVO, Angiography: 2D/3D TOF, 2D/3D phase contrast vascular IMAGING MODES Single, multislice, volume study, fast scan, multi slab, cine, localizer H*W*D 240 x 2216,6 x 201,6 cm POWER REQUIREMENTS 480 or 380/415, 3 phase ||
COOLING SYSTEM TYPE Closed-loop water-cooled grad. | | | | | |
| | | | |
| | | |
|
| |
| Look Ups |
| |